A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies (NCT04830137)
A Phase 1, Dose Escalation, Safety and Tolerability Study of NX-2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies
🩺 Plain-English Summary (8th-Grade Level)
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.
Who can join: Review the eligibility criteria below.
Location: City of Hope — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (16 Sites)
- City of Hope — Duarte, California
- University of California Irvine — Orange, California
- University of California San Francisco Medical Center — San Francisco, California
- Sarah Cannon Research Institute at Colorado Blood Cancer Institute — Denver, Colorado
- Mount Sinai Comprehensive Cancer Center — Miami Beach, Florida
- Sarah Cannon Research Institute at Florida Cancer Specialists — Sarasota, Florida
- The University of Chicago Medical Center — Chicago, Illinois
- National Institutes of Health Clinical Center — Bethesda, Maryland
- Memorial Sloan Kettering Cancer Center — New York, New York
- University of Cincinnati Medical Center — Cincinnati, Ohio
- OSU Wexner Medical Center — Columbus, Ohio
- Tennessee Oncology — Nashville, Tennessee
- Baylor University Medical Center — Dallas, Texas
- MD Anderson Cancer Center — Houston, Texas
- Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah
- Swedish Cancer Institute — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (415) 230-7806
Email: nx2127001@nurixtx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Lymphocytic Leukemia (CLL)
- The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL) — Stanford, California
- Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax — Basking Ridge, New Jersey
- A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies — New York, New York
- Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL — Stamford, Connecticut
- A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL) — Houston, Texas
- Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib — Bethesda, Maryland
Explore by condition: All Chronic Lymphocytic Leukemia (CLL) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.